TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21029897

Group type: EXPERIMENTAL
Intervention: Bilateral implantation of AcrySof IQ ReSTOR +3.0 IOL (model SN6AD1)
Number of subjects: 147
Study: 18572432

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg + Acetaminophen 1000 mg (RA)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Acetaminophen alone (A)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Rizatriptan alone (R)
Number of subjects: 173
Study: 11750189

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9142805

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ; 5/25 mg/[kg x d])
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8433249

Group type: EXPERIMENTAL
Intervention: Decalcified freeze-dried bone allograft (DFDBA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flap procedure for debridement (FPD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polylactic acid (PLA) granules
Number of subjects: 10
Study: 3315397

Group type: EXPERIMENTAL
Intervention: 1% amino acid dialysis solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 0
Study: 30014516

Group type: EXPERIMENTAL
Intervention: Riboflavin (20mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28086943

Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake (170 g/day) and vigorous physical activity (3 × 45 minutes/week) for 6 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake and vigorous physical activity
Number of subjects: 26
Study: 24366918

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly
Number of subjects: 141
Study: 24160383

Group type: EXPERIMENTAL
Intervention: Surgical simulator training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional wet-lab training
Number of subjects: 21
Study: 21912474

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily for 2 weeks, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 week
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Rabeprazole, amoxicillin, and clarithromycin
Number of subjects: 195
Study: 19138183

Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction (CA) used for 1 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: ADA manual toothbrush used for 2 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: ADA manual toothbrush used for 5 min
Number of subjects: 40
Study: 16912957

Group type: EXPERIMENTAL
Intervention: MDR1 3435C‐‐>T variant
Number of subjects: 0
Study: 12960415

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-switch from deferiprone to deferoxamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post-switch from deferoxamine to deferiprone
Number of subjects: 10
Study: 10975769

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 12 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 12 weeks (only patients with normal mucosa at baseline)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks (only patients with normal mucosa at baseline)
Number of subjects: 104
Study: 8931749

Group type: EXPERIMENTAL
Intervention: T-activin therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 17
Study: 1306673

Group type: EXPERIMENTAL
Intervention: Colgate Precision toothbrush
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 126
Study: 31618138

Group type: EXPERIMENTAL
Intervention: Fast speech rate condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Slow speech rate condition
Number of subjects: 50
Study: 28248711

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27150028

Group type: EXPERIMENTAL
Intervention: miRNA-1233 in acute PE (1st day)
Number of subjects: 72
Study: 23725026

Group type: EXPERIMENTAL
Intervention: Cortical freeze-dried bone allograft (FDBA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cancellous freeze-dried bone allograft (FDBA)
Number of subjects: 40
Study: 22353027

Group type: EXPERIMENTAL
Intervention: Exposure to prosmoking media
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control prompts
Number of subjects: 135
Study: 22009784

Group type: EXPERIMENTAL
Intervention: Medial-sided augmentation (MSA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lateral-sided augmentation (LSA)
Number of subjects: 42
Study: 18279486

Group type: EXPERIMENTAL
Intervention: Panoramic visor respirator
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Binocular visor respirator
Number of subjects: 22

Group type: COMPARATOR
Intervention: No mask (unprotected)
Number of subjects: 22
Study: 16106120

Group type: EXPERIMENTAL
Intervention: Left ventricular assist device therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsatile devices
Number of subjects: 0
Study: 12899586

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice daily, for 4 weeks
Number of subjects: 14
Study: 10229434

Group type: EXPERIMENTAL
Intervention: BASRI (Bath Ankylosing Spondylitis Radiology Index) scoring system
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: BASRI scoring system
Number of subjects: 550
Study: 8697339

Group type: EXPERIMENTAL
Intervention: 100 micrograms misoprostol inserted vaginally
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo similarly applied
Number of subjects: 62
Study: 2059974

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1,000 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1,500 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 2,500 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In situ enamel insert model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral fluoride pharmacokinetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F uptake to demineralised enamel
Number of subjects: 0
Study: 6131254

Group type: EXPERIMENTAL
Intervention: Solarium exposure (suntan treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age and sex matched concurrent controls)
Number of subjects: 0
Study: 31865625

Group type: EXPERIMENTAL
Intervention: Reduction of visual and auditory stimuli
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 31495232

Group type: EXPERIMENTAL
Intervention: Night Shift (NS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Day Shift/Days Off (DSDO)
Number of subjects: 22
Study: 29388414

Group type: EXPERIMENTAL
Intervention: Endocervicoscopy (group A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No additional examination (group B)
Number of subjects: 170
Study: 26316575

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 179
Study: 25186131

Group type: EXPERIMENTAL
Intervention: Flexible incobotulinumtoxinA (Xeomin®) injections at intervals of 6-20 weeks, with doses of ≤ 50 U/eye for blepharospasm and 120 U or 240 U for CD.
Number of subjects: 1282

Group type: COMPARATOR
Intervention: IncobotulinumtoxinA 120 U or 240 U for cervical dystonia.
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Placebo for cervical dystonia.
Number of subjects: 1282
Study: 21472883

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (sham laser)
Number of subjects: 60
Study: 19195793

Group type: EXPERIMENTAL
Intervention: Cortisol response in schizophrenia patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cortisol response in matched controls
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heart rate and mean arterial pressure response
Number of subjects: 60
Study: 17518213

Group type: EXPERIMENTAL
Intervention: Subsyllabic method (self-paced version)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subsyllabic method (automatic syllable identification version)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control method (based on phonemic awareness, assisted reading, and other psycholinguistic exercises)
Number of subjects: 63
Study: 15370635

Group type: EXPERIMENTAL
Intervention: Chair-side plaque test (Dentocult SM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Chair-side saliva test
Number of subjects: 65

Group type: COMPARATOR
Intervention: Laboratory method
Number of subjects: 65
Study: 11250995

Group type: EXPERIMENTAL
Intervention: Fenretinide treatment (5-year duration)
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2867
Study: 9648698

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP) 200 microg four times daily for 6 days
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Subjects with positive cultures for S. pneumoniae, H. influenzae, or M. catarrhalis
Number of subjects: 199
Study: 7978538

Group type: EXPERIMENTAL
Intervention: Inhaled beta‐adrenergic agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AeroChambers and InspirEase kits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asthma mortality rates
Number of subjects: 0
Study: 2537582

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31264940

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavioral therapy (CBT) for anxiety
Number of subjects: 35
Study: 31045449

Group type: EXPERIMENTAL
Intervention: Neutropenic diet recommended
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutropenic diet not recommended
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutropenic diet not addressed
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evidence backing recommendations
Number of subjects: 20
Study: 28235970

Group type: EXPERIMENTAL
Intervention: Pure Self-Directed (PSD) intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Guided Self-Directed (GSD) intervention
Number of subjects: 200
Study: 25668777

Group type: EXPERIMENTAL
Intervention: 4 weeks of cycling training (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single 15‐minute cycling session
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (control group, n=10)
Number of subjects: 20
Study: 23054601

Group type: EXPERIMENTAL
Intervention: Manipulation of hand weight during reaching tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated exposure to the same perturbation
Number of subjects: 0
Study: 21205247

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator at 0.9 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline) 100 ml
Number of subjects: 0
Study: 18285727

Group type: EXPERIMENTAL
Intervention: CMV pp65 antigen
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CMV IgM antibody
Number of subjects: 67
Study: 17121345

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Anaerobic endurance training
Number of subjects: 41
Study: 15228257

Group type: EXPERIMENTAL
Intervention: CQ-AS (Chloroquine combined with Artesunate)
Number of subjects: 300

Group type: COMPARATOR
Intervention: CQ (Chloroquine alone)
Number of subjects: 300
Study: 10859547

Group type: EXPERIMENTAL
Intervention: 3D conditions
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2D conditions
Number of subjects: 34
Study: 8686975

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg every 12 hours
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg every 12 hours
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg, plus rifampin, 300 mg every 12 hours
Number of subjects: 111

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ofloxacin plus rifampin
Number of subjects: 111
Study: 2051576

Group type: EXPERIMENTAL
Intervention: M1-blocker; pirenzepine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: H2-blocker; ranitidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 6341272

Group type: EXPERIMENTAL
Intervention: Smoking prevention programme
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Younger cohort
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Older cohort
Number of subjects: 6000
Study: 30394006

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (2 × 500 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29994792

Group type: EXPERIMENTAL
Intervention: Compression gloves
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard rehabilitation (control)
Number of subjects: 32
Study: 28376754

Group type: EXPERIMENTAL
Intervention: TDR surgery
Number of subjects: 144

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation
Number of subjects: 144
Study: 26684653

Group type: EXPERIMENTAL
Intervention: 5 portions FV/day for 16-weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: 2 portions FV/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups (5 portions/day and 2 portions/day)
Number of subjects: 83
Study: 23228626

Group type: EXPERIMENTAL
Intervention: Stabilization (STB) exercises for 6 weeks
Number of subjects: 25
Study: 21247971

Group type: EXPERIMENTAL
Intervention: Continuous exercise at 45% peak power, n=20
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (30 sec on, 30 sec off at 90% peak power), n=21
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined exercise (10 min intermittent at 90% peak power then 10 min continuous at 45% peak power), n=20
Number of subjects: 61
Study: 18715391

Group type: EXPERIMENTAL
Intervention: Dinamap 8100 automated blood pressure machine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual sphygmomanometer
Number of subjects: 0
Study: 16542056

Group type: COMPARATOR
Intervention: MK‐0767 (1-80 mg single doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: MK‐0767 (0.3-25 mg multiple doses once daily for 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: MK‐0767 (25 mg multiple doses once daily for 14 days)
Number of subjects: 8
Study: 12850240

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-users (Control)
Number of subjects: 30
Study: 10940094

Group type: EXPERIMENTAL
Intervention: Solubilized ibuprofen, 400 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Acetaminophen, 1000 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9512820

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 12
Study: 8374092

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 3484773

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 1,000 mg single‐dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice a day for three days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice a day for seven days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 320‐1,600 mg single‐dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 160‐800 mg twice a day for three days
Number of subjects: 5
Study: 29618116

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the rVLPFC
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the rVLPFC
Number of subjects: 44
Study: 26508702

Group type: EXPERIMENTAL
Intervention: 15LEU (70/15/180/30 g protein-leucine-carbohydrate-fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5LEU (23/5/180/30 g protein-leucine-carbohydrate-fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 15LEU and 5LEU
Number of subjects: 12

Group type: COMPARATOR
Intervention: Protein-leucine ingestion
Number of subjects: 12
Study: 25239122

Group type: EXPERIMENTAL
Intervention: Automated telephone nutrition support (ATNS) counseling
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group receiving ATNS phone calls 14 weeks after enrollment
Number of subjects: 75
Study: 23650508

Group type: EXPERIMENTAL
Intervention: High-altitude de-acclimatization syndrome evaluation on the 3rd, 50th, and 100th days after return to low altitude.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Subjects returning to Kunming
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Routine blood and blood gas tests, myocardial zymograms assay
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-altitude de-acclimatization syndrome
Number of subjects: 137
Study: 21092098

Group type: EXPERIMENTAL
Intervention: Care pathways (CP) as complex intervention including formative evaluation, evidence-based key interventions, and support for CP implementation
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 398
Study: 19035086

Group type: EXPERIMENTAL
Intervention: PHS group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mesh-plug group
Number of subjects: 80
Study: 16697496

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid enriched parenteral nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: soy bean lipid emulsion
Number of subjects: 24
Study: 14607440

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise stress test the day after coronary stenting
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No stress test
Number of subjects: 1000
Study: 11012479

Group type: EXPERIMENTAL
Intervention: Omeprazole, Tetracycline, Bismuth, and Clarithromycin (OTBC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amoxycillin, Omeprazole, Tetracycline, and Bismuth (OTBA)
Number of subjects: 31
Study: 8746285

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day) for 28 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 1402620

Group type: EXPERIMENTAL
Intervention: Prednisolone, 25 mg orally, three times daily for 8 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (furosemide and rehydration alone)
Number of subjects: 30
Study: 3768084

Group type: EXPERIMENTAL
Intervention: Preparation A (Salbutax)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Preparation B (commercially available formulation)
Number of subjects: 12
Study: 31642985

Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation therapy (F-BA) for 12 months
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation therapy (F-BA)
Number of subjects: 744
Study: 30392739

Group type: EXPERIMENTAL
Intervention: Obtuse angled earlobes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Acute angled earlobes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Right angled earlobes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Acute angled earlobes in males
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Obtuse angled earlobes in females
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attached type earlobes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attached type earlobes in males
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Attached type earlobes in females
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Comparison of attached vs free type earlobes
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Comparison of earlobe types between sexes
Number of subjects: 1000
Study: 25684312

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 53
Study: 25118092

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 9
Study: 21297126

Group type: EXPERIMENTAL
Intervention: Concurrent radiation therapy (RT) with gefitinib and tipifarnib
Number of subjects: 0
Study: 27945892

Group type: EXPERIMENTAL
Intervention: Vaccine containing Mycobacterium w, administered 0.1 ml intradermally on a weekly basis for 6 to 10 weeks.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vaccine containing Mycobacterium w
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 91
Study: 12017405

Group type: EXPERIMENTAL
Intervention: Clarithromycin ER (two 500-mg tablets once daily for 7 days)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg once daily for 7 days)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Clarithromycin ER
Number of subjects: 176

Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Clarithromycin ER and Trovafloxacin
Number of subjects: 176
Study: 9720828

Group type: EXPERIMENTAL
Intervention: Supportive companion during labour for 1 hour
Number of subjects: 16

Group type: COMPARATOR
Intervention: No supportive companion during labour for 1 hour (control)
Number of subjects: 16
Study: 8018004

Group type: EXPERIMENTAL
Intervention: Use of heparin nomogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin therapy with nomogram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy (rtPA, APSAC) with heparin
Number of subjects: 0